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The potential of ligand binding proteins as drug carriers and delivery systems has recently sparked great interest. We investigated the
potential of tear lipocalin (TL) to bind the antibiotic, rifampin, and the environmental conditions for controlled release. To determine if TL
binds rifampin, gel filtration was used to isolate protein fractions of tears. Rifampin was detected by absorbance spectroscopy in the elution
fractions containing TL. The bound complex of rifampin–TL generates optical activity at about 360 nm, indicating a unique conformation at
the binding site. Rifampin has a higher affinity for TL (Kd = 128 AM) than albumin. Rifampin is released from the TL calyx in acidic
conditions and is displaced by palmitic acid. Autooxidation of free rifampin begins in minutes but is delayed by at least 3 h in the presence of
TL. These properties are conducive to stabilization and delivery of rifampin to tubercles that are acidic and rich in fatty acids. These studies
show the potential of TL as a carrier for rifampin with controlled release to a targeted environment.
D 2003 Elsevier B.V. All rights reserved.Keywords: Tear lipocalin; von Ebner’s gland protein; Rifampin; Tuberculosis; Drug delivery1. Introduction
Drugs that are unstable require stabilization against
oxidation and degradation. If the free drug potentiates toxic
effects, then protein carriers may ameliorate toxicity. Bind-
ing drugs to carriers of high affinity with subsequent
stimulus-induced release permits controlled delivery [1].
Rifampin is a potent broad-spectrum antibiotic limited by
toxicity. It is an ideal drug for the development of a target
carrier system. Here we describe the characteristics for the
interaction of rifampin with a potential carrier protein, tear
lipocalin (TL).
Rifampin acts against pathogens by inhibition of the
bacterial RNA polymerase. Rifampin is a key component
of anti-tuberculosis therapy and is also used for chemopro-
phylaxis, as well as in treatment of some types of meningitis0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2003.11.006
Abbreviations: ANS, 8-anilino-1-naphthalene sulfonate; CD, circular
dichroism; DAUDA, 11-((5-(dimethylamino)-1-naphthalenyl)amino)unde-
canoid acid; HPLC, high-performance liquid chromatography; HSA,
human serum albumin; P646, 3-perylenedodecanoic acid; TL, tear lipocalin
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E-mail address: bglasgow@mednet.ucla.edu (B.J. Glasgow).and fungal infections [2]. Rifampin has been touted as a
potential inhibitor of amyloid aggregation for patients with
Alzheimer’s disease [3].
Despite these uses, rifampin has numerous adverse
effects that include hepatitis, thrombocytopenia, leukopenia,
hemolytic anemia, and renal insufficiency. Rifampin has
potentially harmful interactions with other drugs, often due
to rifampin-induced augmentation of the hepatic cyto-
chrome P450 oxidase system [4]. The adverse affects of
rifampin have been related to free drug concentration in
plasma and are inversely related to the degree of protein
binding [5]. At therapeutic doses, about 80% of serum
rifampin is protein-bound, mostly to albumin. The remain-
ing 20% diffuses freely into tissues [6]. One approach to
reduce toxicity is to use a carrier protein that has a greater
affinity for rifampin than albumin and yet features selectiv-
ity for targeting to the right environment, in this case the site
of tuberculosis infection [1,7].
The proteins of the lipocalin family have been suggested
as potential drug carriers [1]. Certain features of TL merit
consideration as a rifampin carrier. TL binds small hydro-
phobic molecules particularly fatty acids, fatty alcohols,
glycolipids, phospholipids and cholesterol in tears [8]. Re-
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motif of a cup-shaped binding cavity that is formed by an
eight-stranded antiparallel h-sheet closed back on itself to
form a continuously hydrogen-bonded h-barrel [9,10]. TL is
more promiscuous than some other lipocalins. The small size
and the flexibility of the E–F loop may facilitate access of
ligands into the cavity mouth. In the solution structure model,
four alanine residues are positioned in the binding site in TL
as compared to bulkier residues in the corresponding posi-
tions of a structurally similar lipocalin, h-lactoglobulin. The
smaller residues permit broad promiscuity in TL that might
partially accommodate the bulky naphthol ring structure (Fig.
1) of rifampin [10]. TL is secreted by the lacrimal gland, von
Ebner’s gland, bronchial epithelium, sweat glands, prostate
and the pituitary but it is not found in blood [11–15]. TL is
known to release some ligands at low pH [16]. 11-((5-
(dimethylamino)-1-naphthalenyl)amino)undecanoid acid
(DAUDA), a ligand with a naphthyl ring structure (Fig. 1),
is effectively displaced from TL by palmitic acid and stearic
acid [17]. Since the environment of tuberculous granulomata
is acidic and replete with fatty acids [18,19], it is possible that
TL might function to selectively deliver rifampin in this
setting.
A number of observations led to the hypothesis that TL
would bind rifampin with higher affinity than albumin. In
patients ingesting rifampin, the tears may exhibit a red color.
In tears, the concentration of albumin (3–40 Ag/ml) is much
lower than in serum (32–45mg/ml). The concentration of TL
(1.2 mg/ml) is much greater in tears than the concentration ofFig. 1. Chemical structures of DAUDA, P646 and rifampin.albumin [20]. The binding protein for rifampin in tears has
not been previously identified. In saliva of patients taking the
drug, rifampin is concentrated, saliva/plasma ratio = 1.6, but
the concentration of albumin (80 Ag/ml) is lower than in
serum [21,22]. TL is secreted in saliva by von Ebner’s glands
of the tongue [11,23]. Finally, in the process of expressing TL
in bacterial culture, we initially used rifampin to relatively
augment plasmid production of protein. TL appeared red in
color suggesting rifampin was present. These findings
prompted us to investigate the potential of TL as a rifam-
pin-binding protein with properties facilitating selective
delivery to sites of tuberculous infection.2. Methods
2.1. Tear fractionation and tear lipocalin purification
Whole human tears were stimulated and collected
from healthy donors as previously described [8]. Rifam-
pin (Amersham Life Sciences, Arlington Heights, IL),
375 AM final concentration, in 1 ml tears was applied to
a 2.5 100 cm column of Sephadex, G-100 (Pharmacia)
and eluted with 50 mM Tris–HCl and 100 mM NaCl
(pH 7.2). Fractions were monitored for rifampin and
protein at 475 and 280 nm, respectively. Fractions from
the peaks at 280 nm were pooled and analyzed by SDS
PAGE as previously described [24]. TL was purified and
delipidated as published [8,25].
2.2. Absorption spectroscopy
UV absorption spectra were recorded at room temper-
ature using a Shimadzu UV-2401PC spectrophotometer
(Columbia, MD). The concentration of human serum
albumin (HSA), fatty acid-free, globulin-free (Sigma, St.
Louis, MO) was determined using e280 = 36,520 M
 1
cm 1 [26]. The normalization and determination of peak
absorbances were performed using software provided by
Shimadzu. For experiments studying the binding of ri-
fampin to albumin, 580 AM HSA was used. In experi-
ments saturating albumin with fatty acids, a solution
containing 580 AM HSA, 4 mM palmitic acid was
vortexed for 2 min, and centrifuged. Rifampin was added
to the supernatant containing saturated HSA.
For autooxidation experiments, a wavelength of about 474
nm was found to be most sensitive for detection of oxidative
products. 1,10-phenanthroline monohydrate (Sigma) and
nitrogen gas were used to remove divalent metal ions and
oxygen, respectively, from the samples.
2.3. CD spectroscopy
Spectra were recorded with a J-810 spectropolarimeter
(Jasco, Easton, MD), 10 mm path length for the near-UV
spectra. In general, eight scans in the range of 250–450
Fig. 2. Gel filtration profile of tears in the presence of rifampin (total concentration, 375 AM). Tear proteins and rifampin profiles were monitored by means of
absorbance at 280 nm (–o– ) and 475 nm (–.– ), respectively. The composition of each peak is indicated. Inset, SDS tricine 10% acrylamide gel. Lane 1
contains molecular weight standards; lanes 2 and 3, pooled G-100 fractions 30–50;, 2 Ag protein; lanes 4 and 5, fractions 57–70, 2.7 Ag protein; lanes 6 and 7,
fractions 70–82, 1 Ag protein; lane 8, fractions 85–110, 20 Al; lanes 9 and 10, contain human tears, 0.5 Al; lane 11, tear lipocalin 0.5 Ag. Samples in lanes 2,4,6
and 9 were run under non-reducing conditions.
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of protein and rifampin together. To reduce the duration of
scans for titration experiments, the range most sensitive for
rifampin binding, 320–450 nm was scanned. Results were
recorded in millidegrees.
For rifampin binding experiments monitored by circular
dichroism (CD) spectroscopy, rifampin 21 AM in 10 mM
sodium phosphate, 100 mM NaCl, pH 7.3, was titrated
against TL. The change in the magnitude of the optical
activity at k~360 nm, was used to calculate bound protein
according to the formula:
½Proteinbound ¼ ðDCD=DCDmaxÞ½Rifampintotal
The value of DCDmax was obtained by nonlinear
regression techniques. The amount of free protein is
obtained from the difference of total protein and calculat-
ed bound protein. The data were analyzed in terms of the
modified Scatchard equation, which is a rectangular
hyperbola:
½Proteinbound=½Rifampintotal ¼ n½Proteinfree
=ðKd þ ½ProteinfreeÞwhere n is binding stoichiometry. The calculated data
were fitted by standard nonlinear regression techniques
(using Microcal ORIGIN software, Northampton, MA) to
a single rectangular hyperbola to give estimates of Kd
and n.
For competitive binding experiments of rifampin with
apo-TL and HSA, CD spectroscopy was performed as
described above.
2.4. Mass spectrometry
For the determination of masses of rifampin before
and after oxidation samples were analyzed by electro-
spray ionization/flow injection analysis on a QSTAR XL
hybrid quadrupole time-of-flight mass spectrometer (MDS
Sciex, Toronto, ON). The QSTAR XL was operated in
the positive ion mode with a needle voltage of 4800 V.
Initial mass assignment was determined with the aid of
an internal standard, A19L, a synthetic peptide of known
mass 2025.11, using the TOF mode. Selected ions of
both rifampin and oxidized rifampin were analyzed by
MS/MS to identify the fragments that contained the site
of oxidation.
Fig. 3. (A) Rifampin binding to TL. CD spectra of apo-TL (50 AM), pH 7.3
(– – ); rifampin (10 AM), pH 7.3 (: : :); apo-TL (50 AM) with rifampin (10
AM), pH 7.3 (—). (B) Ligand binding curve for rifampin and apo-TL. Kd
and n are the dissociation constants and stoichiometry, respectively. The
experiments were performed at pH 7.3. The fitting curve is indicated (—).
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Our results show that TL binds rifampin. Protein
fractions separated by G-100 chromatography verified
co-elution of rifampin and TL (Fig. 2). Because rifampin
was added in seven-fold molar excess to TL in tears
prior to the chromatography, free rifampin elutes as the
trailing peak in the non-protein fraction (fractions 85–
110, Fig. 2). Under the conditions chosen, TL is known
to elute as a dimer in fractions 57–70 [27], MW~34,000
Da but there are some oligomers that account for some
minor absorption in fractions 30–50 (Fig. 2). SDS gel
electrophoresis confirmed our previous observation that
the majority of TL was present in fractions 57–70 and a
minor amount was present in fractions 30–50 [27].
Rifampin did not elute with fractions 70–82, which
contain lysozyme.
The binding of rifampin to TL was monitored by the
induced optical activity of rifampin at 359 nm. TL has
no optical activity in this region (Fig. 3A). Using the
change in optical activity at 359 nm, the dissociation
constant for the rifampin–TL complex was calculated to
be Kd = 128 AM with stoichiometry n = 0.94 (Fig. 3B).
In order to determine if rifampin binds in the cavity of
TL, we performed displacement experiments with palmitic
acid. The difference CD spectrum (Fig. 4 inset), free
rifampin subtracted from that bound to TL, shows the
peaks of optical activity at 335.5 and 359 nm that reflect
protein binding. The optical activity induced by rifampin
binding to TL is markedly diminished when palmitic acid
is added (Fig. 4) indicating displacement of rifampin from
the cavity of TL.
Optical activity is not induced by rifampin binding to
HSA despite a greater than six-fold molar excess of HSA
to rifampin (Fig. 4). In order to study the potential
displacement of rifampin from HSA by fatty acids, it
was necessary to monitor the absorbance spectrum. The
spectrum of free rifampin is blue shifted (peak at 473.2
nm) compared to that of rifampin bound to HSA (peak at
474.8 nm) (Fig. 5). Despite the fact that fatty acids bind to
HSA with much higher affinity than rifampin, no signifi-
cant blue shift is detectable in the presence of palmitic
acid. Furthermore, the addition of rifampin to HSA that
had been saturated with palmitic acid yields a similar
spectrum as observed with the complex of rifampin and
fatty acid-free-HSA. Rifampin neither displaces palmitic
acid from HSA nor is displaced from some specific fatty
acid binding site of HSA by palmitic acid.
Because there is no optical activity generated from the
complex of rifampin to HSA, a competitive displacement
experiment was plausible to more directly compare the
affinity of rifampin to HSA versus apo-TL. CD spectra
show that when HSA was added in increasing concen-
tration to the complex of rifampin–apo-TL, optical ac-
tivity remained unchanged despite a 4.2 molar excess of
HSA (Fig. 6).The effect of pH on rifampin binding to TL is shown
in Fig. 7. CD spectra show reduced optical activity at
about 359 nm for the rifampin–TL complex at pH 3
compared to pH 7.3. Also evident in the near UV
spectrum is a diminished negative signal in the range
of 275–290 nm. Optical activity in this region is asso-
ciated with rigidity of aromatic side chains in the protein.
The diminished rifampin binding occurs concomitantly
with the relaxation in aromatic side chain rigidity at low
pH (Fig. 7).
The oxidation of free rifampin can be monitored by
diminished absorbance at about 473 nm and increased
absorbance at about 560 nm [28]. Autooxidation is
complete by 24 h (Fig. 8) and is dependent on the
presence of at least trace amounts of divalent ions (Fig.
9). TL confers protection from autooxidation for at least
3 h (Fig. 9, inset). A strong oxidizing agent such as
Fig. 4. Rifampin binding to apo-TL and HSA. Near UV CD spectra of rifampin (21 AM), pH 7.3 (—); rifampin (21 AM) and apo-TL (140 AM) pH 7.3 (– – );
rifampin (21 AM) and apo-TL (140 AM) with the addition of palmitic acid (210 AM), pH 7.3 (–*–). Rifampin (21 AM) and HSA (155 AM), pH 7.3 (–.– ).
Inset: difference CD spectra of rifampin (21 AM) and apo-TL (140 AM) pH 7.3.
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9). Oxidation was nearly eliminated by removing either
oxygen or divalent ions from the samples (Fig. 9, inset).
To confirm that autooxidation of rifampin involved mod-
ification of the hydroquinone ring, we performed mass
spectrometry. Treatment of rifampin with K3Fe(CN)6
resulted in the shift in mass of the major peak assigned
to rifampin of 823.41–821.39 Da (Fig. 10). MS/MS of
these two ions resulted in the appearance of 399.1 and
397.12 Da fragments, respectively (Fig. 10, inset). The
best assignment for the 399.1 Da fragment was a
structure of formula C20H22N405, predicted mass 399.4,
containing the hydroquinone ring and missing the ali-
phatic bridge of rifampin of predicted mass 399.4 Da
(Fig. 10A, left). The results with autooxidation were
similar.4. Discussion
4.1. Rifampin binding to TL in tears
These experiments clearly demonstrate that rifampin
binds to TL in tears as well as purified TL. This result is
in keeping with the fact that rifampin is lipophilic and TL is
the major lipid-binding protein in tears. Our data indicatethat the binding of rifampin to TL generates optical activity
presumably related to a unique conformation of the bound
chromophore [29]. The change in optical activity associated
with rifampin binding facilitated the observation and quan-
titation of binding to TL. In contrast, the rifampin–HSA
complex does not generate additional optical activity com-
pared to free rifampin. The bound chromophore does not
assume a unique conformation probably because HSA has
numerous binding sites for rifampin.
4.2. Comparison of rifampin binding to TL and HSA
Rifampin is readily displaced from TL by palmitic acid.
However, palmitic acid does not displace rifampin from
albumin. Palmitic acid has distinctive hydrophobic interac-
tions with residues of the cavity in TL; the free energy
differences in fatty acid binding is associated with length of
the carbon chain [30]. The respective dissociation constants,
albeit by different methods, indicate that rifampin has a
greater binding affinity for TL (Kd = 128 AM) than for
albumin (Kd = 218 AM) [6].
While rifampin binding to albumin is quite weak at
multiple binding sites, the opposite is true for bacterial
RNA polymerase. Rifampin binds in a hydrophobic
pocket of the RNA polymerase beta subunit deep within
the DNA/RNA channel [31]. A cluster of hydrophobic
Fig. 5. The effect of palmitic acid on rifampin binding to HSA. (A)
Absorbance spectra of rifampin (21 AM), pH 7.3 (: : :); rifampin (21 AM)
and HSA (580 AM), pH 7.3 (—); rifampin (21 AM) and HSA (580 AM)
saturated with palmitic acid, pH 7.3 (– – ). (B) Rifampin binding to HSA
saturated with palmitic acid. Absorbance spectra of rifampin (21 AM), pH
7.3 (: : :); Rifampin (21 AM) and HSA saturated with palmitic acid (580
AM), pH 7.3 (—).
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van der Waals’ contact with the napthol ring and methyl
group at C7 of rifampin. Our data suggest that rifampin
binds within the lipocalin fold. It is possible that the
lipophilic napthol ring and methyl group of rifampin
interact with amino acid residues that form an internal
hydrophobic cluster of TL [30,32]. Given the large size of
the rifampin molecule (Fig. 1), it is reasonable to spec-
ulate that steric hindrance would limit penetration of the
lipocalin calyx. Previous studies have indicated that the
TL cavity does not admit the perylene ring of 3-peryle-
nedodecanoic acid (P646) (Fig. 1) diameter 9.1 A˚ [30].
Steric factors may explain the weaker binding of rifampin
to TL than the bacterial RNA polymerase; 50% inhibition
of the bacterial RNA polymerase is achieved with 0.02
AM of rifampin [33]. The possibility that rifampin binds
to TL at an external hydrophobic patch seems implausible
since fatty acids displace rifampin and are known to bind
in the internal binding site [34]. This selective displace-ment of rifampin by fatty acids raises the potential for
controlled delivery.
4.3. Protection from autooxidation of rifampin is conferred
by TL
It is evident from Fig. 8 that free rifampin undergoes
oxidation within minutes. The oxidation is nearly complete
after 24 h. TL clearly delays the onset of oxidation by at
least 3 h (Fig. 9). The spectroscopic changes during autoox-
idation that we observed are similar to changes described for
oxidation of rifampin in the presence of metal ions [28]. The
mass spectrometry results confirm a loss of two atoms of
hydrogen that represent an oxidation of naphthohydroqui-
none structure of rifampin to the naphthoquinone form. It is
evident from the data that the autooxidation of rifampin
requires the presence of divalent cations and oxygen. A
mechanism for the oxidation of organic molecules has been
described that is catalyzed by a trace metal–oxygen com-
plex [35]. It is likely that this mechanism is responsible for
the autooxidation of rifampin. The precise way in which TL
confer protection from this process is not clear.
4.4. The potential of TL as a drug carrier
Our data show that rifampin may be released from TL
in an acidic environment. Previous studies have indicated
that the acid conditions result in decreased but retained
h-structure in TL, increased 8-anilino-1-naphthalene sul-
fonate (ANS) binding as well as release of native lipids,
fatty acids and alkyl amides [16]. These findings eviden-
tiate that acidic conditions produce a molten globule state
in TL associated with lipid binding. A similar mecha-
nism is probably operative for TL and rifampin. The
implication is that acidic conditions such as those en-
countered at the sites of mycobacterial infection, may
stimulate the release of rifampin. A combination of
factors including local inflammation with accumulation
of lactic acids and phagosomal acidification, may drop
the pH of tubercles to 5.0 or lower [19]. In addition, the
high concentration of fatty acids produced by mycobac-
teria at these sites [18] could locally displace rifampin
from TL leading to a high concentration of antibiotic in
the area of infection.
It is evident from this study that TL is the main
rifampin-binding protein in tears. For patients taking
rifampin, TL will act as its carrier in the tear film.
The uses of rifampin in the tear film are limited because
isolated mycobacterial keratitis is usually non-tuberculous
and not sensitive to rifampin [36,37]. TL is also present
in the mouth. While many bacterial and fungal infections
that occur in the mouth may be sensitive to rifampin, it
is not generally used in this setting [38]. The interaction
of TL to rifampin raises the possibility of using TL as a
potential specific carrier as an aerosol or in the blood
with properties conducive to targeted delivery. Aerosol-
Fig. 6. Titration of rifampin–apo-TL complex with increasing concentrations of HSA. CD spectra of rifampin (24 AM) alone pH 7.3 (D–D), The overlapping
solid lines represent the 10 individual spectra of apo-TL (140 AM) and rifampin (24 AM) pH 7.3 alone, and with progressively increasing concentrations of
HSA (50, 98.0, 146, 192, 238, 283, 370, 455, and 535 AM), respectively. Inset: the change in the optical activity at 360 nm with increasing HSA is shown.
100% represents the optical activity of the rifampin–apo-TL complex without any HSA.
Fig. 7. Rifampin binding to TL in acidic conditions. CD spectra of apo-TL
(50 AM) with rifampin (10 AM), pH 7.3 (—); apo-TL (50 AM) with
rifampin (10 AM), pH 3.0 (– – ).
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have been used to treat pulmonary infections [39,40].
TL is normally secreted by bronchial epithelium and is
likely to be tolerated well in an aerosol formulation [13].
Because the rifampin HSA complex does not exhibit
optical activity, a direct comparison of rifampin binding
was permitted in the CD spectral titration experiments
(Fig. 6). Because HSA did not reduce the optical activity
induced by the rifampin–apo-TL complex, our CD assay
results corroborated that TL has a much greater binding
constant than HSA for rifampin. The dissociation con-
stant of rifampin that we determined for TL (Kd = 128
AM) compares favorably to the Kd’s (10–1000 AM)
considered as high-affinity binding sites for drugs [41].
The greater binding constant for TL as compared to
albumin implies that less free drug would be available in
serum and hence the toxicity might be reduced. Another
potential factor ameliorating potential toxicity is the
possible accelerated glomerular filtration of TL (~17.5
kDa) because it is much smaller than albumin (~66.5
kDa) [25]. The bound form that incidentally enters the
bloodstream after an aerosol delivery would be quickly
cleared. Because the binding of rifampin to TL occurs in
a unique site of the calyx, it may be possible to alter the
residues lining the TL cavity to enhance binding and
delivery features to further reduce toxicity and improve
targeted delivery. Enhanced binding has been achieved
for a number of selected ligands by altering the loops
joining the h strands of the lipocalin scaffold [42]. Inaddition, a cellular receptor has recently been described
for TL [43,44]. Based on accessibility studies in the
holo- and apo-TL, a receptor recognition site has been
hypothesized to exist on the loop joining h strands F
Fig. 8. Autooxidation of rifampin. Absorbance spectra of rifampin (23 AM)
at pH 7.3 after various times in buffer: (a) 1.5 min; (b) 20 min; (c) 40 min;
(d) 80 min; (e) 120 min; (f) 180 min; (g) 24 h.
Fig. 9. Oxidation of rifampin in the presence of TL. Absorbance spectra of rifampi
(– – ); 20 min (: : :); 40 min (– 		– 		); 80 min (- - - - -.-); 120 min (—	 —	); 180
comparison, absorbance spectra of rifampin alone after autooxidation during 24 h (
of rifampin alone, under N2, and in the presence of the divalent ion chelator, 1,10 p
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interaction of the receptor with TL or the presence of the
receptor in pulmonary epithelium and pneumocytes, it is
an area of intensive study. Once this interaction is known
in detail, it may be possible to engineer the lipocalin
molecule to alter the receptor binding properties by the
technique of combinatorial protein design for more
targeted delivery [45]. These features are particularly
relevant in light of the rapid emergence of resistant
strains of Mycobacterium tuberculosis.5. Conclusions
Our studies confirm the hypothesis that rifampin binds
TL with a higher affinity than HSA. The induced optical
activity demonstrate that binding occurs in a unique
conformation and permitted quantitation of binding con-
stants. Binding and displacement experiments confirm
that rifampin binds in the calyx of TL, is displaced by
long alkyl chains of fatty acids and is released from TL
in an acidic environment. These characteristics, in com-
bination with the physiologic presence of TL in bron-
chial epithelium and the protection conferred againstn (15 AM) and apo-TL (50 AM), pH 7.3 after various time in buffer: 1.5 min
min (–w –w – ); 180 min and addition of K3Fe(CN)6 (90 AM) (–o– ); for
 ) and apo-TL (50 AM) alone (—) are also shown. Inset: autooxidation
henanthroline. Absorbance was measured at 474 nm for rifampin oxidation.
Fig. 10. Mass spectrometry of rifampin before and after oxidation. (A) The main signal is a mass of 823.41 Da corresponding to the predicted mass of rifampin.
Insets: MS/MS spectra reveals a fragment of 399.16 Da consistent with the hydroquinone ring species with the structure as shown. (B). Mass spectrum of
rifampin after treatment with K3Fe(CN)6 (90 AM) reveals the predominant species with a mass of 821.39 Da. Inset: MS/MS spectrum shows a fragment of
397.14 Da consistent with the loss of 2 Da in the hydroquinone structure shown in (A). A synthetic peptide, mass 746.73 Da was used as an internal control.
O.K. Gasymov et al. / Biochimica et Biophysica Acta 1688 (2004) 102–111110oxidation, suggest that TL would be superior to albumin
in a rifampin delivery system for tuberculosis. While
there are many lipocalins that could serve as templates
for the design of drug carriers, TL is especially attractive
for protein engineering, because it offers a capacious
calyx and broad promiscuity of ligand binding.Acknowledgements
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